% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Barba:282296,
      author       = {Barba, Lorenzo and Bellomo, Giovanni and Alcolea, Daniel
                      and Wojdala, Anna L and Gaetani, Lorenzo and Fortea, Juan
                      and Abu-Rumeileh, Samir and Lleó, Alberto and Parnetti,
                      Lucilla and Belbin, Olivia and Otto, Markus and Oeckl,
                      Patrick},
      title        = {{S}erum level changes of the synaptic marker beta-synuclein
                      in {A}lzheimer's disease continuum and other dementias.},
      journal      = {Journal of neurology, neurosurgery, and psychiatry},
      volume       = {96},
      number       = {12},
      issn         = {0022-3050},
      address      = {London},
      publisher    = {BMJ Publishing Group},
      reportid     = {DZNE-2025-01266},
      pages        = {1144 - 1153},
      year         = {2025},
      abstract     = {Beta-synuclein is an emerging blood biomarker for detecting
                      synaptic damage in Alzheimer's disease (AD) but its role in
                      early AD as well as in other dementias is unclear.We
                      measured with immunoprecipitation mass-spectrometry serum
                      beta-synuclein levels in an exploratory cohort of 80
                      patients recruited at the University of Perugia (Perugia,
                      Italy) (n=56 AD; n=24 controls) and in a validation cohort
                      of 269 patients recruited at the University of Barcelona
                      (Barcelona, Spain) (n=108 AD; n=53 frontotemporal lobar
                      degeneration (FTLD); n=73 dementia with Lewy bodies and mild
                      cognitive impairment (MCI) with Lewy bodies, together Lewy
                      body disease (LBD); n=27 controls). We tested associations
                      with diagnostic groups, cognitive decline and other
                      cerebrospinal fluid (CSF) and blood markers (phosphorylated
                      tau protein in position 181 (pTau181), neurofilament light
                      chain protein (NfL), glial fibrillar acidic protein
                      (GFAP)).Serum beta-synuclein level was progressively
                      increased in the AD continuum across the preclinical, MCI
                      and dementia stages compared with controls and was
                      correlated with serum pTau181 (r=0.710), NfL (r=0.494) and
                      GFAP concentrations (r=0.621, p<0.001 for all). The
                      biomarker showed high accuracy for the discrimination of AD
                      vs controls (area under the curve (AUC): 0.87) and AD-MCI vs
                      non-AD MCI (AUC: 0.96). High serum beta-synuclein level was
                      correlated with lower Mini-Mental State Examination (MMSE)
                      points at baseline (r=-0.461, p<0.001) and associated with
                      MMSE change at follow-up after accounting for age, sex and
                      the time from baseline to last follow-up visit (p=0.006).
                      Serum beta-synuclein level was similar between FTLD and
                      controls, whereas, in LBD, it was higher with AD copathology
                      as evidenced by CSF analysis (p<0.001).High serum
                      beta-synuclein level is a promising biomarker for AD-related
                      synaptic damage.},
      keywords     = {Humans / Male / Female / Alzheimer Disease: blood /
                      Alzheimer Disease: cerebrospinal fluid / Aged / Biomarkers:
                      blood / Lewy Body Disease: blood / Lewy Body Disease:
                      cerebrospinal fluid / Cognitive Dysfunction: blood /
                      Cognitive Dysfunction: cerebrospinal fluid / tau Proteins:
                      blood / tau Proteins: cerebrospinal fluid / beta-Synuclein:
                      blood / Aged, 80 and over / Frontotemporal Lobar
                      Degeneration: blood / Frontotemporal Lobar Degeneration:
                      cerebrospinal fluid / Middle Aged / Neurofilament Proteins:
                      blood / Neurofilament Proteins: cerebrospinal fluid / Glial
                      Fibrillary Acidic Protein: blood / Glial Fibrillary Acidic
                      Protein: cerebrospinal fluid / Dementia: blood / Cohort
                      Studies / ALZHEIMER'S DISEASE (Other) / FRONTOTEMPORAL
                      DEMENTIA (Other) / LEWY BODY DEMENTIA (Other) /
                      NEUROCHEMISTRY (Other) / Biomarkers (NLM Chemicals) / tau
                      Proteins (NLM Chemicals) / beta-Synuclein (NLM Chemicals) /
                      neurofilament protein L (NLM Chemicals) / Neurofilament
                      Proteins (NLM Chemicals) / Glial Fibrillary Acidic Protein
                      (NLM Chemicals)},
      cin          = {AG Öckl},
      ddc          = {610},
      cid          = {I:(DE-2719)5000073},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40571405},
      doi          = {10.1136/jnnp-2025-336189},
      url          = {https://pub.dzne.de/record/282296},
}